Center For AIDS Research

October 13-20, 2015

The Network News
October 20-27, 2015
Divider Rule Scientific Voices of the Week ...

Toxoplasma gondii is a ubiquitous protozoa that can wreak havoc in people with HIV, causing encephalitis with focal brain lesions plus some other really bad things. This past August Turing Pharmaceuticals AG bought the exclusive marketing rights to the toxoplasmosis drug Daraprim and jacked its price overnight from $13.50 a pill to $750 a pill. The company CEO defended his actions by saying that even at the new cost the drug was still underpriced relative to its peers AND that they needed the money to fund trials to find a more effective toxo drug.
What do you think?

"No one needs a new drug for toxoplasmosis. It works so well bloody well. ... [Besides] they're not peers. He could have said, 'A bar of gold cost $1 million, so Daraprim is underpriced.'"
- Amir Attaran (University of Ottowa)

"It's clearly the best drug. If I had toxo, I'd want to get Daraprim."
- Carlos del Rio (Emory University)

"This is ridiculous. If a person wants to pay hundreds of thousands of dollars a year for drugs they should just sign up for cystic fibrosis or cancer instead."
- Daniel Smith (Walden College)

Divider Rule Kudos ...

... to some recently promoted CFARians.

     Rana Chakraborty

Rana Chakraborty: Professor (Pediatrics)

     Theresa Gillespie

Theresa Gillespie: Professor (Surgery)

     Vince Marconi

Vince Marconi: Professor (Medicine)

     Kate Winskell

Kate Winskell: Associate Professor (Public Health)

(Are we missing anyone? Let us know!)

Divider Rule In Other News ...

Happy Birthday

... to Guido Silverstri (October 20), Anthony McWilliams (October 21), Tris Parslow (October 22), Eli Rosenberg (October 27)

The only thing better than cake is more cake ... so let's ALL have some cake in honor of you!



Jessica Wells    

The incidence of anal cancer in people with HIV is 28 times higher than in the general population so any insight that new School of Nursing faculty member Jessica Wells can give us into what it takes to successfully propel a person with HIV to seek follow up care after an abnormal cancer screen would be a VERY good thing. Jessica has new K01 funding (1K01NR015733-01A1) to examine the individual-, interpersonal-, neighborhood-level factors that predict adherence to follow-up high-resolution anoscopy after an abnormal anal cancer screen.

    Dan Kalman


Although TB is a global killer of people with HIV, the drugs we have available to fight it are rapidly losing ground in the TB drug-resistance arms race. So wouldn't it be nice if we could increase the arsenal by repurposing an existing drug? Dan Kalman has received new UH2 funding for preclinical and clinical development of the cancer drug Gleevec to treat TB/HIV co- infections. Gleevec appears to be effective at this at low doses AND does not appear to easily engender resistance. The new award (1UH2AI122320-01) will establish dosing and safety parameters in humans and test proof of efficacy for TB/HIV. If successful, Dan's work will have important and immediate therapeutic implications for people co-infected with HIV and TB.

Divider Rule Bulletin Board...

bulletin board

Investigators Seeking Data Wanted: Women's Research Interest Group
WIHS and CFAR are hosting a luncheon on Thursday, 10/22 (see calendar) to describe the data available through WIHS. This is a great opportunity for pre-doctoral students (dissertation research opportunities!), postdoctoral students (research projects!) and faculty (publications using data from the largest and longest running study of women and HIV in the country!)
Read the Agenda
RSVP to Sara Sanford (

Divider Rule Government News...

Government News

   AIDS Info

The AIDSinfo panel on Opportunistic Infections in HIV-Infected Adults and Adolescents has released an update to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.
Read What's New

Divider Rule Focus On...
The New NIH AIDS Research Priorities

Focus On...    

The AIDS funding world has just gotten a whole lot more focused.

Effective with the beginning of NIH fiscal year 2016 (October 1) the NIH started following newly established guidelines for determining whether a proposed research project is high-, medium-, or low-priority for receiving AIDS-designated funding.

Functionally, it is highly probable that only 'high-priority' projects will be paid out of AIDS dollars in FY2016. This matters not just to you as an AIDS resarcher but also to the CFAR as a whole because only grants paid with "AIDS dollars" count towards the funded research base that determines how much money the CFAR receives from NIH.

So, as Carlos del Rio says:
Aim High like the Sky; Medium and Low are No Go."

To help with that, the Developmental Core is developing a workshop on the best way to design and propose High Priority Projects. Stay tuned for details.

Here is a list of the newly established NIH High Priorities for AIDS Research:

Reducing Incidence of HIV/AIDS
This includes developing and testing promising vaccines, developing and testing microbicide and pre-exposure prophylaxis candidates and methods of delivery, especially those that mitigate adherence issues; and developing, testing, and implementing strategies to improve HIV testing and entry into prevention services.

Next generation HIV therapies
These include therapies with better safety and ease of use including: developing and testing HIV treatments that are less toxic, longer acting, have fewer side effects and complications, and easier to take and adhere to than current regimens.

Additionally, implementation research to ensure initiation of treatment as soon as diagnosis has been made, retention and engagement in these services, and achievement and maintenance of optimal prevention and treatment responses.

Research toward a cure
This includes developing novel approaches and strategies to identify and eliminate viral reservoirs that could lead toward a cure or lifelong remission of HIV infection, including studies of viral persistence, latency, reactivation, and eradication.

HIV-associated comorbidities, coinfections, and complications
This includes addressing the impact of HIV-associated comorbidities, including tuberculosis, malignancies; cardiovascular, neurological, and metabolic complications; and premature aging associated with long-term HIV disease and antiretroviral therapy.

Basic Research
This includes understanding the basic biology of HIV transmission and pathogenesis; immune dysfunction and chronic inflammation; host microbiome and genetic determinants; and other fundamental issues that underpin the development of high priority HIV prevention, cure, co-morbidities, and treatment strategies.

Research to Reduce Health Disparities
This includes research in the incidence of new HIV infections or in treatment outcomes of those living with HIV/AIDS.

Research Training
This includes training of the workforce required to conduct High Priority HIV/AIDS or HIV/AIDS-related research.

NOTE: Medium Priority topics will include projects that do not focus solely on AIDS but still demonstrate that HIV/AIDS is a meaningful component of the project and/or that knowledge about HIV will be enhanced by the project, as evidenced in the specific aims.

Divider Rule

Funding Opps


Nothing new this week


October 30, 2015
Sponsor: NIH CFAR
Creative and Novel Ideas in HIV Research (CNIHR)

November 1, 2015
Sponsor: Yerkes
ERASE AIDS Pilot Awards

December 22, 2015
Sponsor: BIRCWH
Mentored Career Development in Women's Health Research

March 1, 2016
Sponsor: ACTSI
KL2 Pilot Awards


See previously advertised Funding Opportunities in Network News archived issues.


Divider Rule pubs

Recent Pubs
linked to the CFAR grant
(P30 AI050409)

Lahiri CD, Reed-Walker K, Sheth AN, Acosta EP, Vunnava A, Ofotokun I. Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens. J Clin Pharmacol. 2015 Aug 6.
PMID: 26247878

Kelley CF, Kahle E, Siegler A, Sanchez T, Del Rio C, Sullivan PS, Rosenberg ES. Applying a PrEP Continuum of Care for Men who Have Sex with Men in Atlanta, GA. Clin Infect Dis. 2015 Aug 13.
PMID: 26270691

Chowdhury A, Del Rio PM, Tharp GK, Trible RP, Amara RR, Chahroudi A, Reyes-Teran G, Bosinger SE, Silvestri G. Decreased T Follicular Regulatory Cell/T Follicular Helper Cell (TFH) in Simian Immunodeficiency Virus-Infected Rhesus Macaques May Contribute to Accumulation of TFH in Chronic Infection. J Immunol. 2015 Aug 21.
PMID: 26297764

Cooper HL, Linton S, Kelley ME, Ross Z, Wolfe ME, Chen YT, Zlotorzynska M, Hunter-Jones J, Friedman SR, Des Jarlais D, Semaan S, Tempalski B, DiNenno E, Broz D, Wejnert C, Paz-Bailey G. National HIV Behavioral Surveillance Study Group. Racialized risk environments in a large sample of people who inject drugs in the United States. Int J Drug Policy. 2015 Aug 8.
PMID: 26342272

Calendar Upcoming Events
October 21
HOPE Webinar
HIV and Cardiovascular Disease: Pathways to Prevention
   Kathleen Fitch, MSN, FNP (Mass Gen)
Focus: Nurses
Sponsor: Harvard CFAR
HOPE Conference Website
To Attend Webinar: Click this link on 10/21

October 21 New Listing
Insights into NIH Funding Opportunities for Pre- and Post-Doctoral Researchers in the Biomedical Sciences
Location: Whitehead Auditorium

October 22
ID Seminar - Faculty Candidate Talk
Surgical Site Infections: Recent Epidemiology and Future Surveillance
Starring: Art Baker, MD, MPH
    (ID Fellow, Duke University Medical Center)
Location: RSPH / GCR / Rita Anne Rollins Room

October 22
1:00 - 2:30
Lunch n' Learn
WIHS/CFAR Women's Research Interest Group
Location: 1599 Bldg/Rm 5C
Read the Agenda
RSVP to Sara Sanford (

October 22 New Listing
1:30 - 2:20pm
Center for Drug Discovery Seminar
Mechanism Underlying HIV-1 Restriction in Myeloid Cells
Starring: Li Wu, PhD
    Ohio State University
Location: HSRB Auditorium

October 22 New Listing
2:30 - 3:30pm
Center for Drug Discovery Seminar
Regulation of SAMHD 1 Antiviral Activity
Starring: Felipe Diaz-Griffero, PhD
    Albert Einstein College of Medicine
Location: HSRB Auditorium

October 27 New Listing
12:30 - 1:30pm
Health Disparaties Seminar
An Intersectional Examination of HIV Risk among African American Girls
Starring: Scyatta Wallace, PhD
    St. Johns University
Location: Morehouse School of Medicine
    National Center for Primary Care/President's Boardroom

Calendar Farther Down the Road
October 28-30
SBSRN 2015
Integrating Social, Behavioral, and Biomedical Strategies: The Future of HIV/AIDS Prevention and Care Research
Host: Johns Hopkins University CFAR
Location: Baltimore

October 29
November 5
11:30am - 1:30pm
Social Occasion
Faculty and Staff Lunch
As a means to foster casual and social interaction, collaboration and community, the Emory Faculty Club Planning Committee has arranged with the Emory Dining Office to establish a new program for faculty and staff to enjoy lunch together
Location: Winship Ballroom, the DUC
Cost: $7 plus tax, All you can eat
• Pay at register at top of spiral staircase

December 1, December 8
11:00 - 1:00pm
2-class series Grant Writing Workshop
For ACTSI KL2 & BIRCWH K12 applicants`
Instructor: Janet Gross
Really Important Information

December 6-9
2015 National HIV Prevention Conference
Accelerating Progress: Prevent Infections. Strengthen Care. Reduce Disparities
Location: Atlanta (Hyatt Regency & Marriott Marquis)

December 6-10
Frontiers in Drug Development for Viral Hepatitis
Location: Wailea, Maui, Hawaii
Abstract Submission Information

May 15-17, 2016 New listing
6th International Conference on Primate Genomics
Location: Potomac Maryland
Abstract Submission Information


Divider Rule
Spotlight Spotlight

Footlights | Vaccine Dinner Club - Wednesday, November 4

Focus: Basic Science

     VDC logo


Talk Title TBA


Eric G. Pamer, MD
Head, Division of General Medicine
Chief, Infectious Diseases Service
Enid A. Haupt Chair in Clinical Investigation
Memorial Sloan Kettering Cancer Center


Divider Rule
CFAR logo

The Network News is a periodic email, detailing HIV/AIDS related events, funding opportunities, and achievements of CFAR members. If you have items that you wish to have included, please send them to us at by Friday of each week. Please put "The Network News" in the subject line.

The Network News is distributed to CFAR members and fans by email every Tuesday. Except when it isn't.

Editor, Kimberley (Kimbi) Sessions Hagen, EdD

Divider Rule
Emory University Center for AIDS Research Emory University Center for AIDS Research